IBRX Stock Slides on FDA Warning Over Misleading Cancer Drug Claims

ImmunityBio shares plunged 21% after the FDA flagged the company's cancer drug Anktiva for making misleading claims, citing exaggerated benefits and inadequate risk disclosures. The FDA notice significantly raises regulatory and legal risk for the company and is likely to damage commercial prospects and investor confidence in the near term.

Analysis

ImmunityBio shares plunged 21% after the FDA flagged the company's cancer drug Anktiva for making misleading claims, citing exaggerated benefits and inadequate risk disclosures. The FDA notice significantly raises regulatory and legal risk for the company and is likely to damage commercial prospects and investor confidence in the near term.